【摘要】 目的研究在老年冠心病患者中,合用CYP3A4酶的底物或抑制剂对阿托伐他汀使用安全性及有效性的影响。研究与阿托伐他汀引起肌病风险相关的危险因素。方法提取某三甲医院2017年3月到6月所有使用阿托伐他汀的老年冠心病患者的临床数据,对数据进行提取整理并用SPSS进行分析,相关的危险因素分析用多元线性回归的方法。结果对于老年冠心病患者,阿托伐他汀与CYP3A4抑制剂合用,对阿托伐他汀的有效性及安全性指标没有显著地影响。但是随着与阿托伐他汀合用的CYP3A4底物数量的增加,CRE值有逐渐升高的趋势。多元线性回归分析显示,与服用阿托伐他汀引起肌病(CK值升高)风险相关的因素有:年龄、性别、血脂异常和合用CYP3A4抑制剂。结论对于阿托伐他汀合用CYP3A4抑制剂和多种CYP3A4底物的老年患者,注意监测患者的安全性指标,特别是CRE和CK值。更多还原

【Abstract】 Objective To study the safety and efficacy of atorvastatin in elderly patients with CAD when combined with substrates and inhibitors of CYP3 A4, so as to find out the risk factors associated with atorvastatin-induced myopathy.Methods The clinical data of elderly patients, who had received atorvastatin, were collected in one research center from March to June in 2017 and analyzed by SPSS. The associated risk factors were analyzed by multivariate linear regression analysis. Results There was no significant effect on the safety and efficacy of atorvastatin for elderly patients with CAD, combined with the inhibitors of CYP3 A4. However, with the increasing number of the substrates of CYP3 A4,CRE showed a rising tendency. According to the result of multivariate linear regression analysis, CK could be influenced by age, gender, dyslipidemia, and the inhibitors of CYP3 A4 in elderly patients with CAD. Conclusion The safety parameters should be monitored when elderly patients received atorvastatin and in combination with CYP3 A4 inhibitors and multiple CYP3 A4 substrates, especially the CRE and CK.更多还原